Skip to main content
Fig. 1 | Cancer Communications

Fig. 1

From: The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study

Fig. 1

Plasma Epstein-Barr virus (EBV) DNA levels in patients with nasopharyngeal carcinoma (NPC). a Plasma EBV DNA levels before the initiation of treatment and before surgery for all 82 patients; b plasma EBV DNA levels before the initiation of treatment for the patients with and without tumor cells detected in dissected cervical lymph nodes; c plasma EBV DNA levels before neck dissection for the patients with and without tumor cells detected in dissected cervical lymph nodes; d plasma EBV DNA levels before the initiation of treatment for all 82 patients according to clinical stage; e plasma EBV DNA levels before the initiation of treatment for all 82 patients according to T stage; f plasma EBV DNA levels before the initiation of treatment for all 82 patients according to N stage

Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us